Recent developments highlight ResMed's Q1 FY2027 financial results with revenue growth, earnings improvement, and strategic portfolio adjustments.

• ResMed reported Q1 FY2027 revenue of $1.4 billion, a 6% increase year-over-year, driven by higher device and mask sales in the Sleep and Breathing Health segment [N2][N3][N1].
• Gross margin improved to 61.5% from 61.2%, reflecting manufacturing efficiencies and lower amortization costs following the MatrixCare sale [N1][S2].
• Diluted earnings per share increased to $2.92 for Q1 FY2027 compared to $2.37 in the prior year period [N3][S2].
• The company declared a quarterly cash dividend of $0.66 per share [N2].
• ResMed completed the sale of its MatrixCare business on September 1, 2026, as part of portfolio optimization to focus on core growth areas [S1][S2].
• Research and development expenses rose 15% to $103 million, representing 7.3% of net revenues, supporting ongoing product innovation [S2].
• The company held a Q1 FY2027 earnings conference call on October 29, 2026 [N4].
• Market commentary discusses ResMed's strong growth profile and recent earnings performance [N5][N6].

ResMed benefits from increasing global awareness and diagnosis of sleep and breathing disorders, a large underpenetrated market. Its continuous innovation in AI-powered devices and cloud-connected health solutions supports improved patient outcomes and therapy adherence. The company's strategic acquisitions expand its clinical portfolio and diagnostic capabilities, while divestitures sharpen focus on core growth areas. Strong financial performance with revenue growth, margin improvement, and robust cash position underpin operational strength. Expansion into adjacent markets like restless legs syndrome and enhanced software offerings provide additional growth avenues.

Risks include potential supply chain disruptions and inflationary pressures on manufacturing inputs, which may affect margins. The competitive landscape in medical devices and digital health is evolving, with new entrants and alternative therapies emerging. Regulatory changes and reimbursement policies could impact product adoption and pricing. The divestiture of the MatrixCare business reduces diversification in software offerings. Patient compliance challenges and technological obsolescence pose ongoing execution risks. Macroeconomic and geopolitical factors may also affect global operations and market demand.

ResMed's moat is built on its leadership in digital health and cloud-connected medical devices for sleep and breathing disorders, supported by a broad product portfolio including CPAP devices, masks, ventilators, and software solutions. Its integration of AI-powered digital health platforms and cloud-based remote monitoring enhances patient adherence and provider efficiency, creating a differentiated ecosystem. The company's global reach, extensive R&D investment, and strategic acquisitions strengthen its competitive position. Regulatory approvals and clinical evidence supporting its therapies further reinforce barriers to entry for competitors.

• Supply Chain and Inflation Risks: Inflationary pressures on manufacturing inputs, especially electronic components, and supply chain expansions may cause margin fluctuations [S2].
• Regulatory and Reimbursement Changes: Changes in healthcare regulations and reimbursement policies could impact product adoption and pricing dynamics [S1][S2].
• Competitive and Technological Risks: Emerging competitors and alternative therapies in sleep and breathing health may challenge market share. Rapid technology changes require continuous innovation [S1].
• Execution Risks from Portfolio Changes: The sale of the MatrixCare business reduces diversification and may impact software segment revenue stability [S1][S2].
• Patient Compliance and Adoption: Effectiveness of CPAP and other therapies depends on patient adherence, which remains a challenge despite product improvements [S1].

• ResMed Inc is a global leader in digital health and cloud-connected medical devices focused on sleep and breathing health and residential care software solutions [S1].
• The company designs AI-powered digital health solutions, cloud-connected devices, and intelligent software to improve home healthcare personalization, accessibility, and effectiveness [S1].
• ResMed's core business includes continuous positive airway pressure (CPAP) therapy devices for obstructive sleep apnea (OSA), masks, ventilation devices, diagnostic products, and related accessories [S1].
• The company also provides cloud-based health applications and software enabling clinicians to manage patients efficiently and improve therapy adherence [S1].
• ResMed operates two segments: Sleep and Breathing Health, and Residential Care Software [S1].
• In June 2026, ResMed acquired Noctrix Health, LLC, expanding its clinical sleep health portfolio into restless legs syndrome treatment [S1].
• In 2025, ResMed acquired VirtuOx, operating a software-enabled independent diagnostic testing facility providing in-home and remote testing services in the U.S. [S1].
• On September 1, 2026, ResMed completed the sale of its MatrixCare business as part of portfolio optimization to focus on core growth areas [S1][S2].
• The company employs approximately 11,370 people and sells products in over 140 countries through subsidiaries and distributors [S1].
• For the three months ended September 30, 2026, ResMed reported net revenue of $1.415 billion, a 6% increase from the prior year period [S2].
• Sleep and Breathing Health segment revenue increased 8% to $1.26 billion for the same period, driven by increased demand and unit sales of devices and masks [S2].
• Residential Care Software segment revenue decreased 7% to $155 million, mainly due to the sale of MatrixCare, partially offset by growth in other verticals [S2].
• Gross margin for Q1 FY2027 was 61.5%, slightly up from 61.2% in the prior year period, reflecting manufacturing efficiencies and lower amortization costs [S2].
• Operating expenses increased, with research and development expenses rising 15% to $103 million, representing 7.3% of net revenues [S2].
• Cash and cash equivalents as of September 30, 2026, totaled approximately $1.01 billion, with a current ratio of 2.65 and a cash ratio of 0.76 [S2].
• Diluted earnings per share for Q1 FY2027 were $2.92, up from $2.37 in the prior year period [S2].
• ResMed's products address a broad range of sleep and breathing disorders including OSA, COPD, overlap syndrome, and neuromuscular diseases [S1].
• The company emphasizes ongoing investment in R&D and product innovation, including recent product enhancements like the AirSense 11 device with touch screen and over-the-air updates [S1][S2].
• ResMed's business model includes both device sales and software-enabled services to improve patient outcomes and healthcare provider efficiency [S1][S2].
• Recent news highlights include Q1 FY2027 revenue of $1.4 billion, dividend declaration of $0.66 per share, and positive earnings and revenue performance [N1][N2][N3][N4].
• The company continues to focus on geographic expansion, acquisitions, and increasing awareness of sleep and breathing health conditions [S1][S2].